MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:37Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Aromatase inhibitors]]
			[[Category:Antineoplastics]]
			[[Category:Endocrine therapy]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #194

2026-05-23T04:00:15Z

parser-claude batch MedTemplate pre-fill, Top 300 #194

New page

{{MedTemplate
| generic = Anastrozole
| brand = Arimidex
| structure =
| classes = [[:Category:Aromatase_inhibitors|Aromatase inhibitor (non-steroidal)]], [[:Category:Antineoplastics|Antineoplastic]], [[:Category:Endocrine_therapy|Endocrine therapy]]
| uses = <vote slug="er-positive-breast-cancer-adjuvant-use">Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women</vote>, <vote slug="er-positive-breast-cancer-advanced-use">Advanced ER-positive breast cancer (postmenopausal)</vote>, <vote slug="breast-cancer-prevention-use">Breast cancer risk reduction (selected high-risk postmenopausal women)</vote>
| starting_dose = 1 mg PO once daily
| preparations = 1 mg tablets
| fda_max = 1 mg/d
| pill_id =
| routes = Oral
| onset = Estrogen suppression within days; clinical effect over months
| duration = 24 hours
| halflife = ~50 hours<ref name="arimidex-label">FDA Prescribing Information, Arimidex (anastrozole), AstraZeneca, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020541s026lbl.pdf</ref>
| bioavailability = High (oral; not significantly affected by food)<ref name="arimidex-label" />
| pregnancy = Contraindicated in pregnancy (only used in postmenopausal women); D class historically.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="anastrozole-mech-claim">Anastrozole is a selective non-steroidal aromatase inhibitor; it reversibly binds the CYP19 (aromatase) enzyme that converts adrenal androgens to estrogens in peripheral tissues (the principal source of estrogen after menopause), producing >97% estrogen suppression in postmenopausal women.</vote> Not effective in premenopausal women because ovarian aromatase is gonadotropin-driven and not adequately suppressed by AI alone. Adverse effects reflect estrogen withdrawal: hot flashes, arthralgias (the "AI joint syndrome"), vaginal dryness, accelerated bone loss (DEXA monitoring; bisphosphonate/denosumab co-therapy common), and modestly increased ischemic CV events in some analyses<ref name="arimidex-label" />.
}}

== References ==
<references />

Anastrozole - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #194